What's New

GalPharma will exhibit at BIO 2007 held in Boston, U.S. from May 6 to May9, 2007.  We will introduce the efficacy data of our stable form ofGalectin-9.
Studies in vitro and in vivo revealed that sGal-9 exhibits versatile immune-regulatory activities in the various immune disorders and showed a great potential as a novel treatment modality for autoimmune and other immunological disorders including rheumatoid arthritis, diabetes and asthma.